我国医保药品支付价格政策改革探讨  

Research on the Payment Pricing Mechanism of Medicare Drugs

作　　者：王青宇[1,2] 高岩[2] 刘伟[2] 郝昕 杨悦[1] 

机构地区：[1]沈阳药科大学工商管理学院,沈阳110016 [2]郑州大学药学院,郑州450001 [3]河南中医学院第一临床医学院,郑州450008

出　　处：《中国药房》2015年第21期2881-2884,共4页China Pharmacy

摘　　要：目的:为我国政府制订医保药品支付价格提供政策建议。方法:阐述医保支付价格政策起源及其他国家实施该政策的效果和出现的问题,在我国新医改背景下结合理论分析及实证研究探讨医保药品支付价格定价机制。结果:药品支付价格政策改革将会对目前医药市场和医疗保险支付产生较大影响,对研发型制药企业的影响和冲击较大。该政策可节约医保资金中药品费用支出,对卫生总费用是否降低有待进一步探索和实践。结论:建议医保政策实施时注意相关配套措施改革。政府应在药品可获得性和鼓励药品研发创新性方面保持平衡。OBJECTIVE：To provide suggestions for the government decision of payment price of medicare drugs. METHODS：Investigation was conducted for the beginning of payment price policy of medicare drugs,effect of the implementation of policy in other countries and the encountered problems. The payment pricing mechanism was explored based on the combination of new medical reform with theoretical analysis and empirical research. RESULTS：The reform of payment pricing mechanism of medicare drugs will have effect on current drug price,especially for RD oriented pharmaceutical industries. The policy can decrease drug expenditure in medicare expenditure,and it is not sure whether it can decrease total medicare expenditure. CONCLUSIONS：It is suggested to notice the related measures and government should keep balance between drug availability and encouraging RD innovation.

关 键 词：支付价格 参考定价 药品定价机制 

分 类 号：R95[医药卫生—药学]